Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma.
Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in...
test
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its...
Descending triangle, Confirmed
Pros
Descending volume
Volume spike on break out
PPS under 50MA
No data on 200MA
No data on 250MA
RS below 0 and descending
Overall bearish
No support under 1,37$
Price Target
PT1 = 2,11 (filled)
PT2 = 1,37
Could see lower
Hello,
Be sure to comment, follow, like, and check out my profile for more trade ideas!
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group’s current drug pipeline includes indications in orphan diseases, infectious...
